8-K: Carlsmed Reports Strong Q4, FY25 Revenue Growth

Carlsmed, a medical technology company, announced preliminary and unaudited revenue for Q4 2025 and full year 2025, showing significant growth.

Summary

• Preliminary fourth quarter 2025 revenue was approximately $15.2 million, representing an approximate 61% increase compared to the fourth quarter 2024.
• Preliminary full year 2025 revenue was approximately $50.5 million, representing an approximate 86% increase compared to the full year 2024.
• Carlsmed added 101 new surgeon users in 2025, increasing its total surgeon user base by 61% over the prior year.
• The company launched aprevo cervical, a patient-specific cervical solution, receiving highly encouraging early surgeon feedback.

Sentiment

Score: 8

Explanation: The filing reports very strong revenue growth for both the quarter and the full year, significant expansion of the user base, and positive feedback on a new product launch. Management commentary is highly optimistic about future growth and market adoption. The only cautionary notes are the preliminary nature of the results and general forward-looking statement disclaimers, which are standard.

Positives

• Strong preliminary Q4 2025 revenue growth of approximately 61% year-over-year to $15.2 million.
• Exceptional preliminary full year 2025 revenue growth of approximately 86% year-over-year to $50.5 million.
• Significant expansion of the surgeon user base, adding 101 new users in 2025, a 61% increase.
• Successful launch of aprevo cervical with positive early surgeon feedback.
• Management expresses confidence in the aprevo platform's potential to improve clinical outcomes and lower healthcare costs.

Risks

• Preliminary unaudited revenue results are estimates only and subject to revision and adjustment until the Company reports its full financial results in its Annual Report on Form 10-K.
• Actual results may differ materially from forward-looking statements due to various important factors, including those set forth under "Risk Factors" in Carlsmed's Registration Statement on Form S-1.

Future Outlook

Management anticipates growing recognition and adoption of the aprevo platform technology in 2026, believing it capable of transforming surgical standards and patient outcomes in spine fusion. The company is focused on executing its strategy for the next phase of growth with operational excellence.

Management Comments

• Our fourth quarter commercial performance capped a transformational year for Carlsmed and underscores the power of aprevo.
• This platform technology provides surgeons with greater procedural predictability and has the potential to meaningfully improve clinical outcomes in spine fusion and lower the total cost of care for the healthcare system.
• With growing enthusiasm for aprevo, we added 101 new surgeon users in 2025, representing a 61% increase in our total surgeon user base over the prior year.
• As we enter 2026, we are focused on executing our strategy for the next phase of growth with operational excellence.
• We are energized by the momentum in our business and the recent launch of aprevo cervical, with highly encouraging early surgeon feedback for our patient-specific cervical solution.
• In 2026, we anticipate growing recognition and adoption of aprevo as a platform technology that we believe is capable of transforming surgical standards and patient outcomes in spine fusion.

Industry Context

Carlsmed operates in the medical technology sector, specifically pioneering AI-enabled personalized spine surgery solutions. This aligns with broader industry trends towards personalized medicine, data-driven healthcare, and the integration of artificial intelligence to improve surgical precision, patient outcomes, and cost efficiency in complex procedures like spine fusion. The focus on lowering the total cost of care is also a significant trend in healthcare.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth and optimistic future outlook, potentially leading to increased share value.
• Employees: Positive impact from company growth and expansion, potentially leading to job security and opportunities.
• Customers (Surgeons/Hospitals): Positive impact from the continued development and adoption of the aprevo platform, offering improved procedural predictability, clinical outcomes, and potentially lower costs of care.
• Patients: Positive impact from access to AI-enabled personalized spine surgery solutions designed to improve outcomes.

Next Steps

• Carlsmed will report its full financial results for 2025 in its Annual Report on Form 10-K.
• The company plans to execute its strategy for the next phase of growth with operational excellence in 2026.
• Carlsmed anticipates growing recognition and adoption of aprevo as a platform technology in 2026.

Key Dates

Recommendation

Carlsmed has demonstrated exceptional preliminary revenue growth of 86% for the full year 2025 and 61% for Q4 2025, significantly expanding its surgeon user base by 61%. The successful launch of aprevo cervical and positive management commentary on the aprevo platform's potential to transform spine surgery and reduce healthcare costs indicate strong operational momentum and a promising future trajectory. While results are preliminary, the magnitude of growth suggests robust market adoption and execution, making it a compelling investment opportunity.

Keywords

Carlsmed, CARL, Medical Technology, Spine Surgery, AI-enabled, Personalized Surgery, Revenue, Financial Results, Q4 2025, FY 2025, aprevo, Surgeon Users, Healthcare, MedTech